RANSAC-based global 3DUS to CT/MR rigid registration using liver surface and vessels

Tsubasa Goto(Fujifilm (Japan)), Waki Koji(Fujifilm (Japan)), Yugo Ishino(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Riki Igarashi(Fujifilm (Japan)), Masafumi Noguchi(Fujifilm (Japan)), Takanori Hirai(Fujifilm (Japan)), Yoshiro Kitamura(Fujifilm (Japan))

International Journal of Computer Assisted Radiology and Surgery

August 21, 2025

10.1007/s11548-025-03498-8

Cited by 0

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

|The Lancet Oncology|2018|2.5k

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

|The Lancet|2023|514

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

|Hepatology Research|2011|77

Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial

|BMC Cancer|2019|77

Mammalian Gcm genes induce Hes5 expression by active DNA demethylation and induce neural stem cells

|Nature Neuroscience|2011|74